Search clinical trials for: Azacitadine

Total 707 results

Jonsson Comprehensive Cancer Center
Stemline Therapeutics, Inc.

Withdrawn

Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
University of Chicago
National Cancer Institute (NCI)

Completed

Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute Myeloblastic Leukemia Without Maturation (M1) | Adult Acute... and other conditions

United States
TJ Biopharma Co., Ltd.

Recruiting

A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes(MDS)

China
Mayo Clinic
National Cancer Institute (NCI)

Completed

Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Childhood Acute Myeloid Leukemia and other conditions

United States
Navy General Hospital, Beijing
Chinese PLA General Hospital

Recruiting

Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Angioimmunoblastic T Cell Lymphoma

Relapsed Angioimmunoblastic T-Cell Lymphoma | Refractory Angioimmunoblastic T-cell Lymphoma

China
Peter MacCallum Cancer Centre, Australia
GlaxoSmithKline; Celgene Corporation

Completed

A Single Arm Pilot Study of Azacitidine in Myelodysplastic Syndromes (MDS) / Acute Myeloid Leukaemia (AML), With Eltrombopag Support for Thrombocytopenia (Aza-E)

Myelodysplastic Syndromes (MDS) | Acute Myeloid Leukaemia (AML)

Australia
Eisai Inc.

Terminated

To Demonstrate Superiority of Decitabine Over Azacitidine in Subjects With Intermediate- or High-risk MDS.

Myelodysplastic Syndromes

United States
M.D. Anderson Cancer Center

Completed

Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 Risk

Leukemia

United States
National Cancer Institute (NCI)

Active, not recruiting

BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Acute Myeloid Leukemia Post Cytotoxic Therapy

United States
Northwestern University
National Cancer Institute (NCI); Boehringer Ingelheim; Robert H. Lurie Cancer...

Active, not recruiting

Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A | Fibroblast Growth Factor Basic Form Measurement | FLT3 Internal Tandem Duplication

United States
Navy General Hospital, Beijing

Recruiting

Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma

Refractory Classic Hodgkin Lymphoma | Relapsed Classic Hodgkin Lymphoma

China
University of Birmingham

Active, not recruiting

Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT (AMADEUS)

Acute Myeloid Leukemia | Myelodysplasia

United Kingdom
Nanexa AB
Uppsala University

Completed

Pharmacokinetics, Tolerability and Safety of NEX-18a

Myelodysplastic Syndromes (MDS) | Acute Myeloid Leukemia (AML) | Chronic Myelomonocytic Leukemia (CMML)

Sweden
M.D. Anderson Cancer Center
Novartis Pharmaceuticals; Celgene Corporation

Completed

PKC412 and 5-Azacytidine

Leukemia

United States
Barbara Burtness

Recruiting

5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC

Squamous Cell Carcinoma of Head and Neck

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome

Leukemia | Myelodysplastic Syndrome | Recurrent Myelodysplastic Syndrome

United States
The First Affiliated Hospital of Soochow University

Enrolling by invitation

Clinical Study of Venetoclax Combined With Azacytiside in the Treatment of Myelodysplastic/Myeloproliferative Neoplasms in Adults

Myelodysplastic/Myeloproliferative Neoplasms | Adult

China
Celgene

Completed

Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia

Myelodysplastic Syndromes (MDS) | Chronic Myelomonocytic Leukemia (CMML) | Acute Myelogenous Leukemia (AML)

United States
Bristol-Myers Squibb

Active, not recruiting

A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes

Argentina, Canada, France, Germany, Italy, Korea, Republic of, Poland, United States, Australia, China, Czechia, Denmark, Greece, Hong Kong, Japan, Spain, Sweden
Yale University

Completed

Window Trial 5-aza in HNSCC, T-tare

Head and Neck Squamous Cell Carcinoma

United States
Celgene

Completed

Alternative Dosing Regimens of Subcutaneous Azacitidine for Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Acute Bilineal Leukemia and other conditions

United States
M.D. Anderson Cancer Center
Syros Pharmaceuticals Inc.

Withdrawn

Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia

Chronic Myelomonocytic Leukemia

United States
National University Hospital, Singapore
The N.1 Institute for Health (N.1); Cancer Science Institute of Singapore

Not yet recruiting

Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI

Breast Cancer | Solid Tumor | Gastrointestinal Cancer

Singapore
Patrick Stiff

Recruiting

Vidaza and Valproic Acid Post Allogeneic Transplant for High Risk AML and MDS

Myelodysplastic Syndrome MDS | Acute Myelogenous Leukemia AML

United States
Groupe Francophone des Myelodysplasies
Merck Sharp & Dohme LLC

Terminated

Addition of Vorinostat to Azacitidine in Higher Risk MDS a Phase II add-on Study in Patients With Azacitidine Failure (GFM-AZA-VOR)

Myelodysplastic Syndrome

France
Novartis Pharmaceuticals

Completed

Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS

Myelodysplastic Syndromes | Bone Marrow Diseases | Hematologic Diseases | Leukemia | Leukemia, Myeloid | Leukemia, Myeloid, Acute | Preleukemia | Chronic Myelomonocytic Leukemia

United States, France, Australia, Netherlands, Spain, Germany, United Kingdom, Finland
Tel-Aviv Sourasky Medical Center

Unknown

Safety And Efficacy Of Azacitidine, and Lenalidomide In Higher Risk Myelodysplastic Syndrome (ViLen 001)

Myelodysplastic Syndrome

Israel
Virginia Commonwealth University

Not yet recruiting

Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From Health-Inequality (REMAIN1)

Acute Myeloid Leukemia

United States
Bristol-Myers Squibb

Recruiting

A Post-Marketing Surveillance Study to Assess the Safety of Oral Azacitidine Maintenance Therapy in Korean Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia

Korea, Republic of
Innovent Biologics (Suzhou) Co. Ltd.

Suspended

Safety and Efficacy of IBI188 With Azacitidine in Subjects With Newly Diagnosed Higher Risk MDS

Myelodysplastic Syndromes

China
Henry Ford Health System

Recruiting

Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant

Myeloid Malignancy

United States
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Terminated

Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.

Myelodysplastic Syndromes | Myelofibrosis | Myeloproliferative Neoplasms

China
Celgene

Completed

Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Leukemia, Myelomonocytic, Chronic

United States
Mayo Clinic
National Cancer Institute (NCI)

Terminated

Azacitidine in Treating Patients With Myelofibrosis

Chronic Myeloproliferative Disorders | Secondary Myelofibrosis

United States
University Hospital Muenster
Celgene Corporation; Amgen

Completed

Efficacy of 5-azacytidine Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) (AML-AZA)

Acute Myeloid Leukemia

Germany
Grupo Cooperativo de Hemopatías Malignas

Withdrawn

Pharmacoeconomics in the Application of 5-azacitidine in the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia

Acute Myeloid Leukemia | Myelodysplastic Syndromes

Mexico
Celgene

Completed

A Phase 1 Study to Evaluate the Pharmacokinetics and Tolerability of Oral Azacitidine in Japanese Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes

Japan
Washington University School of Medicine

Completed

Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) in Combination With Azacitidine for the Treatment of Myelodysplastic Syndrome (MDS) (MDS)

Myelodysplastic Syndromes

United States
King Fahad Medical City

Unknown

Azacytidine Plus FLAG for Relapsed or Refractory AML

Acute Myeloid Leukemia

Saudi Arabia
Stanford University
Celgene Corporation

Completed

Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML) | Adult Acute Myeloblastic Leukemia

United States
Chinese PLA General Hospital

Recruiting

Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Newly Diagnosed Acute Myeloid Leukemia

Acute Myeloid Leukemia

China
Aprea Therapeutics

Completed

APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)

MDS

United States, France
Celgene

Completed

Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function (RENAL)

Multiple Myeloma | Non-Hodgkin's Lymphoma | AML | Solid Tumors | MDS | Hodgkin's Disease

United States
Guangdong Provincial People's Hospital
Shenzhen Chipscreen Biosciences Co.Ltd

Recruiting

A Study of Chidamide With AZA in MRD Positive AML After Transplant

Minimal Residual Disease | AML, Adult

China
Celgene

Completed

Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma (RACE)

Lymphoma | Acute Myeloid Leukemia | Myelodysplastic Syndromes | Multiple Myeloma | Leukemia, Myelomonocytic, Chronic

United States
Washington University School of Medicine

Completed

A Phase II Study of Intravenous Azacitidine Alone in Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Recruiting

Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia

Acute Myeloid Leukemia

France, Korea, Republic of, Spain, United Kingdom, Hungary, Poland
Aprea Therapeutics

Terminated

APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes | MDS

United States
Grupo Cooperativo de Estudio y Tratamiento de las...
Celgene Corporation; Germans Trias i Pujol Hospital; Hospital Son Llatzer

Unknown

Treatment of High Risk Myelodysplastic Syndromes (MDS) Not Candidates for Allogeneic Transplantation of Hematopoietic Progenitors (ALO-HSCT)

Myelodysplastic Syndromes

Spain

Search clinical trials for: Azacitadine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Portugal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations